Holen Sie sich die Stockscreener-App
7.46
2.86%
-0.22
Handel nachbörslich:
7.83
0.37
+4.96%
Schlusskurs vom Vortag:
$7.68
Offen:
$7.67
24-Stunden-Volumen:
235.58K
Relative Volume:
0.92
Marktkapitalisierung:
$173.15M
Einnahmen:
$155.00K
Nettoeinkommen (Verlust:
$-30.01M
KGV:
-4.4671
EPS:
-1.67
Netto-Cashflow:
$-11.98M
1W Leistung:
+0.40%
1M Leistung:
+2.47%
6M Leistung:
+56.72%
1J Leistung:
-29.36%
1-Tages-Spanne:
$7.43
$7.92
1-Wochen-Bereich:
$7.19
$8.0602
52-Wochen-Spanne:
$4.32
$11.03
Inmune Bio Inc Stock (INMB) Company Profile
Firmenname
Inmune Bio Inc
Sektor
Branche
Telefon
(858) 964-3720
Adresse
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Vergleichen Sie INMB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
7.46 | 172.45M | 155.00K | -30.01M | -11.98M | -1.67 |
|
ONC
Beigene Ltd Adr
|
236.49 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.32 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.24 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.62 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.09 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-21 | Eingeleitet | Alliance Global Partners | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-22 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-06-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-05-24 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
| 2021-04-21 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-22 | Bestätigt | Maxim Group | Buy |
| 2020-09-01 | Eingeleitet | BTIG Research | Buy |
| 2020-07-15 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Inmune Bio Inc Aktie (INMB) Neueste Nachrichten
Where are the Opportunities in (INMB) - news.stocktradersdaily.com
Dimensional Fund Advisors LP Acquires 10,491 Shares of INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio: XPro Trial Readout In Alzheimer’s Disease Offers Big Opportunity (NASDAQ:INMB) - Seeking Alpha
Wells Fargo & Company MN Buys 2,155 Shares of INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio to Attend RBC Healthcare Conference - TipRanks
INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference - The Manila Times
INmune Bio Sets Stage for Key Biotech Insights at RBC Healthcare Conference Next Week - Stock Titan
Raymond James raises INmune Bio stock target to $23 - MSN
Barclays PLC Increases Stake in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 - MSN
INmune Bio, Inc. (NASDAQ:INMB) Q1 2025 Earnings Call Transcript - Insider Monkey
INmune Bio’s Earnings Call: Promise and Challenges - TipRanks
Mariner LLC Acquires New Holdings in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
Earnings call transcript: INmune Bio Q1 2025 shows narrowed losses, stock rises - Investing.com
INmune Bio Reports Q1 2025 Results and Updates - TipRanks
INMUNE BIO Earnings Results: $INMB Reports Quarterly Earnings - Nasdaq
INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update - The Manila Times
(INMB) Trading Signals - news.stocktradersdaily.com
INmune Bio appoints new accounting firm By Investing.com - Investing.com Nigeria
INmune Bio appoints new accounting firm - Investing.com
INmune Bio Inc (INMB) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
JPMorgan Chase & Co. Has $53,000 Stock Holdings in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th - The Manila Times
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on ... - Eagle-Tribune
Renaissance Technologies LLC Increases Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
LPL Financial LLC Boosts Stock Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Receives $22.80 Average PT from Analysts - Defense World
INmune Bio (INMB) Expected to Announce Quarterly Earnings on Thursday - Defense World
Geode Capital Management LLC Has $1.70 Million Stock Position in INmune Bio, Inc. (NASDAQ:INMB) - Defense World
A stock that deserves closer examination: INmune Bio Inc (INMB) - uspostnews.com
(INMB) Technical Data - news.stocktradersdaily.com
Inmune Bio Secures Favorable Patentability Opinion for CORDStrom™ - TipRanks
INmune Bio secures key patent opinion for CORDStrom platform By Investing.com - Investing.com South Africa
INmune Bio Receives Favorable Opinion from USPTO on CORDStrom Patent Application - marketscreener.com
INmune Bio Inc. Achieves Key Patent Milestone for CORDStrom™ Cell Therapy Platform - Nasdaq
INmune Bio secures key patent opinion for CORDStrom platform - Investing.com
Patent Win: INmune Bio's Revolutionary Cell Therapy Secures 20+ Years Protection - Stock Titan
INmune Bio (INMB) Partners with CGT Catapult for Large-Scale Cel - GuruFocus
INmune Bio Partners with Cell and Gene Therapy Catapult - MSN
INmune Bio (INMB) Partners to Enhance Cell Therapy Production - GuruFocus
INmune Bio in pact with Cell and Gene Therapy Catapult (INMB) - Seeking Alpha
INmune Bio, CGT Catapult Partner To Scale CORDStrom Manufacturing For Commercial Launch - Nasdaq
INmune Bio Collaborating With Cell and Gene Therapy Catapult to Scale Manufacturing - MarketScreener
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness - The Manila Times
INmune Bio's Game-Changing Partnership Accelerates CORDStrom Production for 4,000 RDEB Patients - Stock Titan
Inmune Bio Presents Alzheimer’s Trial Data at Conference - TipRanks
INmune Bio, Inc. (NASDAQ:INMB) Receives $22.80 Average Price Target from Brokerages - Defense World
Trend Tracker for (INMB) - news.stocktradersdaily.com
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update - ADVFN
INmune Bio Presents MINDFuL Trial Data At AD/PD 2025 - Nasdaq
Finanzdaten der Inmune Bio Inc-Aktie (INMB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.52%
1.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):